Drug Trial Radar · NCT07582159
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Dec 19, 2026
Primary completion
Apr 14, 2029
Study completion Apr 14, 2029
Sponsor
- Lead sponsor
- City of Hope Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests the safety, side effects and how well giving tafasitamab with acalabrutinib and venetoclax works for the treatment of chronic lymphocytic leukemia (CLL)/small cell lymphoma (SLL). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Tafasitamab is a monoclonal antibody that binds to CD19 antigen which is found on the surface of most B cells (a type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantle cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving tafasitamab with acalabrutinib and venetoclax may be safe and effective for treating patients with CLL/SLL.
Conditions
- Chronic Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Small Lymphocytic Lymphoma
Interventions
AcalabrutinibDrug
Given PO
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Computed TomographyProcedure
Undergo CT scan
Positron Emission TomographyProcedure
Undergo PET scan
TafasitamabBiological
Given IV
VenetoclaxDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of unacceptable toxicityTime frame: From cycle 1 day 1 to completion of cycle 4 (cycle length = 28 days)
- Complete response with undetectable minimal residual disease (MRD)Time frame: At the end of therapy after a minimum of 4 cycles
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.